Bone mass in children with congenital hypothyroidism treated with thyroxine since birth.
To determine whether the large doses of thyroxine treatment early in life adversely affect bone mass, we measured bone mass of 20 congenital hypothyroid (CH) patients (8.4 +/- 2.2 years) who were diagnosed and treated since birth. Starting thyroxine dose and current dose were 8.5 +/- 1.9 micrograms/kg/day and 3.1 + 1.2 micrograms/kg/day respectively. Thyroid function and serum biochemical tests for calcium homeostasis were normal at the time of study. Bone mass was measured by dual energy X-ray absorptiometry. Nine siblings served as controls. The patients' bone mineral density was within the normal range of population controls, and was not different from the sibling controls. The patients also had height-adjusted bone mineral content equal to the expected height-adjusted values in the siblings. Our studies indicate that the large doses of thyroxine therapy for CH do not cause osteopenia in childhood.
Kooh
S W
SW
Department of Pediatrics and Physics, University of Toronto, Ontario, Canada.
Brnjac
L
L
Ehrlich
R M
RM
Qureshi
R
R
Krishnan
S
S
D015502:Absorptiometry, Photon; D000293:Adolescent; D001827:Body Height; D015519:Bone Density; D002648:Child; D003409:Congenital Hypothyroidism; D005260:Female; D006801:Humans; D007037:Hypothyroidism / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D012016:Reference Values; D013974:Thyroxine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
D013974:Thyroxine